Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy plus toripalimab for high-risk lymph node metastatic cervical cancer
ChiCTR2500109708Phase 2Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Cervical Cancer (CC), sponsored by Yunnan Cancer Hospital. Primary endpoint: objective response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500109708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109708.